Montrouge, France, November 10, 2020DBV
Technologies to Highlight Data on
Viaskin™ Peanut Treatment
Delivery and Patient Experience at ACAAI 2020
Meeting also will feature virtual industry symposium on
managing food allergies amid the COVID-19 pandemic
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that new analyses of
clinical studies investigating epicutaneous immunotherapy to treat
peanut allergy with a patch (DBV712 250 µg) will be presented at
the virtual American College of Allergy, Asthma & Immunology
(ACAAI) Annual Scientific Meeting, Nov. 13-15, 2020. Four abstracts
have been accepted, including one oral presentation and three
poster presentations. DBV will also host a virtual booth in the
ACAAI virtual exhibit hall.
The data to be presented include assessment of
clinical study patient experiences, the impact of patch adhesion
and duration of patch application on treatment response, and the
performance of an assay for predicting desensitization to peanut.
These analyses contribute to the continued characterization of the
benefit:risk profile of DBV712 250 µg.
DBV is sponsoring an industry symposium during
the conference about the impact of COVID-19 on managing food
allergies. Dr. Matthew Greenhawt, Associate Professor, Pediatrics
and Director, Food Challenge and Research Unit, Children’s Hospital
Colorado, University of Colorado, will discuss the recent expert
panel consensus aiming to guide decision-making in allergy and
immunology clinics during the pandemic with a focus on best
practices for food allergy care, as well as implications for the
future of the field. DBV is also sponsoring the 29th Annual FIT
Bowl, a game show that tests the knowledge of participating teams
from training programs around the country.
“Peanut allergy places a significant burden on
both patients and their families, often due to uncertainty around
accidental exposure. Daily challenges have only increased as the
COVID-19 pandemic has left families with new barriers to allergy
care, including the need to postpone or shift to a telehealth
format for many routine visits, as well as concerns about whether
to seek in-person emergency care after using epinephrine for an
allergic reaction.” said Dr. Pharis Mohideen, Chief Medical Officer
of DBV Technologies. “Our presentations at ACAAI support DBV’s
continued commitment to improving the lives of patients through
innovative treatments and ensuring those treatments are delivered
in the most effective way possible, while better understanding the
need for flexible approaches in light of the pandemic.”
Viaskin™ Peanut (DBV712 250 μg) is the Company’s
lead product candidate designed to potentially reduce the risk of
allergic reactions due to accidental exposure to peanuts. An
investigational non-invasive, once-daily, epicutaneous patch,
Viaskin Peanut seeks to deliver microgram quantities of peanut
antigen to activate the immune system. Viaskin Peanut is based on
epicutaneous immunotherapy (EPIT™), DBV’s proprietary method of
delivering biologically active compounds to the immune system
through intact skin.
DBV Abstracts and Symposium:
Oral Presentation
“Specific Peanut Epitopes as a Biomarker for
Desensitization During Epicutaneous Immunotherapy” will be
presented by David Fleischer, M.D., Children’s Hospital Colorado,
University of Colorado (joint submission with AllerGenis).
- Session Code: 7202
- Session Title: Oral Abstracts - Allergy
Diagnostics/Aerobiology/Food Allergy
- Presentation Date: Saturday, Nov. 14, 2020
- Presentation Time: 3:33 p.m. – 3:47 p.m. CT
Poster Presentations
All three e-posters will be accompanied by recorded author
presentations and will be available on-demand at
college.acaai.org/eposters beginning on Friday, Nov. 13, 2020 at
9:30 a.m. CT.
“An Evaluation of Factors Influencing
Response to Epicutaneous Immunotherapy for Peanut Allergy in the
PEPITES Trial” will be presented by Amy Scurlock, M.D.,
Department of Pediatrics, University of Arkansas for Medical
Sciences and Arkansas Children’s Hospital.
“Evaluation of Daily Patch Application Duration for
Epicutaneous Immunotherapy for Peanut Allergy” will be
presented by Jonathan Spergel, M.D., Ph.D., Children’s Hospital of
Philadelphia.
“Patient Experiences with Epicutaneous Immunotherapy for
Peanut Allergy in OLFUS-VIPES & REALISE Trials: Qualitative
Studies” will be presented by Gordon Sussman, M.D., Gordon
Sussman Clinical Research.
Industry Symposium
“Managing Food Allergy During the COVID-19 Pandemic and
Implications for the Future” will be presented by Matthew
Greenhawt, M.D., Children’s Hospital Colorado, University of
Colorado.
- Symposium Date: Saturday, November 14, 2020
- Symposium Time: 9:35 a.m. – 10:00 a.m. CT
About DBV Technologies
DBV Technologies is developing Viaskin™, an
investigational proprietary technology platform with broad
potential applications in immunotherapy. Viaskin is based on
epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering
biologically active compounds to the immune system through intact
skin. With this new class of non-invasive product candidates, the
Company is dedicated to safely transforming the care of food
allergic patients. DBV’s food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France and offices in Bagneux, France,
and North American operations in Summit, NJ and New York, NY. The
Company’s ordinary shares are traded on segment B of Euronext Paris
(Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one-half of one ordinary share) are traded on the
Nasdaq Global Select Market (Ticker: DBVT).
Forward Looking Statements
This press release may contain forward-looking
statements and estimates, including statements regarding the
therapeutic potential of Viaskin™ Peanut as a treatment for
peanut-allergic children. These forward-looking statements and
estimates are not promises or guarantees and involve substantial
risks and uncertainties. At this stage, the products of the Company
have not been authorized for sale in any country. Among the factors
that could cause actual results to differ materially from those
described or projected herein include uncertainties associated
generally with research and development, clinical trials and
related regulatory reviews and approvals, including the impact of
the COVID-19 pandemic, and whether initial or interim results from
a clinical trial will be predictive of the final results of the
trial or the results of future trials. Furthermore, the timing of
any action by any regulatory entity cannot be guaranteed,
particularly in light of the COVID-19 pandemic. A further list and
description of these risks, uncertainties and other risks can be
found in the Company’s regulatory filings with the French Autorité
des Marchés Financiers, the Company’s Securities and Exchange
Commission filings and reports, including in the Company’s Annual
Report on Form 20-F for the year ended December 31, 2019, and
future filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of
the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
Investor Relations ContactAnne
Pollak+ 1 (857) 529-2363anne.pollak@dbv-technologies.com
Media ContactAngela Marcucci+ 1
(646) 842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Sep 2023 to Sep 2024